GGrantIndex
← Leaderboards

Confometrx, Inc.

Palo Alto, CA

Compare ↔
$8,653,007
Total funding
10
Grants

Funding over time

peak $1.4M · FY200623
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$8,653,007 · 10

By mechanism

R44$7,157,634 · 4
R43$1,495,373 · 6

Investigators at Confometrx, Inc.

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Largest grants

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands$764,531
R44 · FY2020 · MH
Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands$738,119
R44 · FY2021 · MH
Structure-based discovery of dopamine D1 receptor selective small molecule ligands$676,062
R44 · FY2019 · MH
Structure-based discovery of dopamine D1 receptor selective small molecule ligands$676,062
R44 · FY2020 · MH
Structure-based discovery of dopamine D1 receptor selective small molecule ligands$676,062
R44 · FY2021 · MH
Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands$659,183
R44 · FY2019 · MH
Structure-based Drug Discovery for the GLP-1 Receptor$494,338
R44 · FY2017 · DK
Structure-based Drug Discovery for the GLP-1 Receptor$467,338
R44 · FY2016 · DK
Structure-based discovery of dopamine D1 receptor selective small molecule ligands$381,468
R44 · FY2018 · MH
Structure-based discovery of dopamine D1 receptor selective small molecule ligands$376,468
R44 · FY2017 · MH
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS$333,000
R44 · FY2012 · MH
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS$333,000
R44 · FY2013 · MH
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS$333,000
R44 · FY2014 · MH
Discovery of GPR75 small molecule ligands for the treatment of obesity$303,375
R43 · FY2023 · DK
Discovery of GPR171 small molecule ligands for the treatment of chronic pain$298,313
R43 · FY2023 · NS
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS$250,000
R43 · FY2011 · MH
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS$250,000
R43 · FY2010 · MH
Structure-based Drug Discovery for the GLP-1 Receptor$249,003
R44 · FY2015 · DK
Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands$193,685
R43 · FY2017 · MH
Developing Methods for Crystallizing Class B GPCRs$100,000
R43 · FY2009 · GM